Sign In
Buy CGEM
$16.50
-1.02 (-5.82%)
At Close: Jul 31, 2026
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 1,345 Shares
05:00am, Tuesday, 23'rd Dec 2025
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 1,345 shares of the firm's stock in a transaction dated Friday, December 19th. The stock was sold at an av
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock
05:50am, Monday, 22'nd Dec 2025
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 2,898 shares of the firm's stock in a transaction on Thursday, December 18th. The stock was sold at an ave
Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript
04:37am, Tuesday, 09'th Dec 2025
Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
07:00am, Thursday, 20'th Nov 2025
PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune d
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
07:00am, Thursday, 06'th Nov 2025
Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to b
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate obse
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a cl
Cullinan Therapeutics: Worthy Of A Small Position
07:01am, Friday, 17'th Oct 2025
Cullinan Therapeutics is down some 70% since May 2024, mainly due to lack of data from its autoimmune candidate CLN-978. CLN-978, an off-the-shelf CD19xCD3 T-cell engager, targets autoimmune diseases
PRINCETON, N.J. and CAMBRIDGE, Mass.
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
11:26am, Tuesday, 23'rd Sep 2025
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
07:00am, Friday, 12'th Sep 2025
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies
Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
10:50am, Wednesday, 10'th Sep 2025
Cullinan Therapeutics, Inc. (NASDAQ:CGEM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Chad Messer Nadim Ahmed - President, CEO & Direct
